Michael Ulz
Stock Analyst at Morgan Stanley
(3.96)
# 636
Out of 4,712 analysts
109
Total ratings
46.3%
Success rate
13.49%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Ulz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLN Silence Therapeutics | Reiterates: Overweight | $49 | $7.10 | +590.14% | 10 | Oct 8, 2024 | |
| VKTX Viking Therapeutics | Reiterates: Overweight | $105 | $41.16 | +155.10% | 2 | Sep 12, 2024 | |
| DYN Dyne Therapeutics | Maintains: Overweight | $48 → $52 | $23.72 | +119.22% | 2 | Aug 14, 2024 | |
| YMAB Y-mAbs Therapeutics | Maintains: Underweight | $12 → $11 | $8.00 | +37.50% | 6 | Aug 13, 2024 | |
| THRD Third Harmonic Bio | Upgrades: Overweight | $12 → $20 | $10.26 | +94.93% | 4 | Aug 9, 2024 | |
| BPMC Blueprint Medicines | Maintains: Equal-Weight | $110 → $115 | $89.40 | +28.64% | 9 | Jul 12, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $250 → $255 | $237.97 | +7.16% | 8 | Jul 12, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Overweight | $53 → $57 | $41.56 | +37.15% | 3 | Jun 18, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Equal-Weight | $36 → $27 | $18.96 | +42.41% | 4 | May 13, 2024 | |
| KYTX Kyverna Therapeutics | Initiates: Overweight | $40 | $3.99 | +902.51% | 1 | Mar 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $7 | $1.61 | +334.78% | 8 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $1.97 | +813.71% | 1 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $1 → $0.5 | $0.46 | +9.41% | 4 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $25 | $2.29 | +991.70% | 5 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $45 → $48 | $35.91 | +33.67% | 4 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $33 | $28.25 | +16.81% | 3 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $27 | $8.25 | +227.27% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $4 | $0.70 | +470.61% | 4 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $23 | $7.37 | +212.08% | 3 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $30 → $20 | $3.92 | +410.20% | 3 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $11.75 | +282.98% | 1 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $10 | $0.97 | +928.59% | 3 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $6 → $8 | $1.30 | +515.38% | 5 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $3 | $1.75 | +71.43% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $18 → $30 | $7.47 | +301.88% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $25 → $30 | $6.37 | +370.96% | 3 | Mar 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $7.32 | +514.75% | 1 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $20 | $1.50 | +1,233.33% | 2 | May 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $80 | $43.42 | +84.25% | 3 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $15 | $9.63 | +55.76% | 3 | Jul 12, 2017 |
Silence Therapeutics
Oct 8, 2024
Reiterates: Overweight
Price Target: $49
Current: $7.10
Upside: +590.14%
Viking Therapeutics
Sep 12, 2024
Reiterates: Overweight
Price Target: $105
Current: $41.16
Upside: +155.10%
Dyne Therapeutics
Aug 14, 2024
Maintains: Overweight
Price Target: $48 → $52
Current: $23.72
Upside: +119.22%
Y-mAbs Therapeutics
Aug 13, 2024
Maintains: Underweight
Price Target: $12 → $11
Current: $8.00
Upside: +37.50%
Third Harmonic Bio
Aug 9, 2024
Upgrades: Overweight
Price Target: $12 → $20
Current: $10.26
Upside: +94.93%
Blueprint Medicines
Jul 12, 2024
Maintains: Equal-Weight
Price Target: $110 → $115
Current: $89.40
Upside: +28.64%
Alnylam Pharmaceuticals
Jul 12, 2024
Maintains: Equal-Weight
Price Target: $250 → $255
Current: $237.97
Upside: +7.16%
Mirum Pharmaceuticals
Jun 18, 2024
Maintains: Overweight
Price Target: $53 → $57
Current: $41.56
Upside: +37.15%
Arrowhead Pharmaceuticals
May 13, 2024
Maintains: Equal-Weight
Price Target: $36 → $27
Current: $18.96
Upside: +42.41%
Kyverna Therapeutics
Mar 4, 2024
Initiates: Overweight
Price Target: $40
Current: $3.99
Upside: +902.51%
Feb 27, 2024
Maintains: Equal-Weight
Price Target: $3 → $7
Current: $1.61
Upside: +334.78%
Feb 27, 2024
Initiates: Overweight
Price Target: $18
Current: $1.97
Upside: +813.71%
Jan 5, 2024
Downgrades: Underweight
Price Target: $1 → $0.5
Current: $0.46
Upside: +9.41%
Nov 29, 2023
Maintains: Overweight
Price Target: $28 → $25
Current: $2.29
Upside: +991.70%
Nov 3, 2023
Maintains: Equal-Weight
Price Target: $45 → $48
Current: $35.91
Upside: +33.67%
Oct 11, 2023
Maintains: Overweight
Price Target: $70 → $33
Current: $28.25
Upside: +16.81%
Aug 16, 2023
Maintains: Outperform
Price Target: $15 → $27
Current: $8.25
Upside: +227.27%
Aug 7, 2023
Maintains: Equal-Weight
Price Target: $5 → $4
Current: $0.70
Upside: +470.61%
May 23, 2023
Maintains: Outperform
Price Target: $20 → $23
Current: $7.37
Upside: +212.08%
Mar 24, 2023
Maintains: Equal-Weight
Price Target: $30 → $20
Current: $3.92
Upside: +410.20%
Feb 1, 2023
Initiates: Overweight
Price Target: $45
Current: $11.75
Upside: +282.98%
Jan 27, 2023
Maintains: Overweight
Price Target: $20 → $10
Current: $0.97
Upside: +928.59%
Jan 27, 2023
Maintains: Equal-Weight
Price Target: $6 → $8
Current: $1.30
Upside: +515.38%
Jan 27, 2023
Downgrades: Equal-Weight
Price Target: $3
Current: $1.75
Upside: +71.43%
Jan 27, 2023
Upgrades: Equal-Weight
Price Target: $18 → $30
Current: $7.47
Upside: +301.88%
Mar 30, 2022
Maintains: Equal-Weight
Price Target: $25 → $30
Current: $6.37
Upside: +370.96%
Oct 8, 2020
Initiates: Outperform
Price Target: $45
Current: $7.32
Upside: +514.75%
May 28, 2020
Maintains: Outperform
Price Target: $12 → $20
Current: $1.50
Upside: +1,233.33%
Nov 3, 2017
Maintains: Outperform
Price Target: $85 → $80
Current: $43.42
Upside: +84.25%
Jul 12, 2017
Maintains: Outperform
Price Target: $12 → $15
Current: $9.63
Upside: +55.76%